Co-delivery of daunomycin and oxaliplatin by biodegradable polymers for safer and more efficacious combination therapy

Xiao, Haihua; Li, Wenliang; Qi, Ruogu; Yan, Lesan; Wang, Rui; Liu, Shi; Zheng, Yonghui; Xie, Zhigang; Huang, Yubin; Jing, Xiabin

doi:10.1016/j.jconrel.2012.06.004

Cited by 110 publications

(86 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, the combination of DOX and cisplatin could show a highly synergistic potency, and suppress the growth of tumor cells more efficiently than a single drug. [41][42][43] In this study, chemotherapeutic drug was utilized as a cross-linker to construct a novel dual-drug co-delivery system for the combined delivery of DOX and Pt(IV). The amphiphilic diblock copolymer PCL-b-P(OEGMA-co-AzPMA) was synthesized, and then DOX was encapsulated in the hydrophobic core of the micelles.…”

Section: Introductionmentioning

confidence: 99%

Platinum covalent shell cross-linked micelles designed to deliver doxorubicin for synergistic combination cancer therapy

Zhu¹,

Xiao²,

Tang³

et al. 2017

IJN

View full text Add to dashboard Cite

The preparation of polymer therapeutics capable of controlled release of multiple chemotherapeutic drugs has remained a tough problem in synergistic combination cancer therapy. Herein, a novel dual-drug co-delivery system carrying doxorubicin (DOX) and platinum(IV) (Pt[IV]) was developed. An amphiphilic diblock copolymer, PCL-b-P(OEGMA-co-AzPMA), was synthesized and used as a nanoscale drug carrier in which DOX and Pt(IV) could be packaged together. The copolymers were shell cross-linked by Pt(IV) prodrug via a click reaction. Studies on the in vitro drug release and cellular uptake of the dual-drug co-delivery system showed that the micelles were effectively taken up by the cells and simultaneously released drugs in the cells. Futhermore, the co-delivery polymer nanoparticles caused much higher cell death in HeLa and A357 tumor cells than either the free drugs or single-drug-loaded micelles at the same dosage, exhibiting a synergistic combination of DOX and Pt(IV). The results obtained with the shell cross-linked micelles based on an anticancer drug used as a cross-linking linkage suggested a promising application of the micelles for multidrug delivery in combination cancer therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Platinum covalent shell cross-linked micelles designed to deliver doxorubicin for synergistic combination cancer therapy

Zhu¹,

Xiao²,

Tang³

et al. 2017

IJN

View full text Add to dashboard Cite

show abstract

“…Some NDCDS of CDDP plus PTX, or DTX, or rapamycin were studied to get a synergistic efficacy for ovarian cancer and melanoma (Cai et al, 2014;Guo et al, 2014;Song et al, 2014b). Similar synergistic effects were got in the evaluation on co-delivery of daunomycin and oxaliplatin by biodegradable polymers for enhanced anticancer therapy (Xiao et al, 2012a). The other co-delivery of small molecule chemotherapeutic drugs, for instance, TPT and vincristine (Zucker et al, 2012), irinotecan and DOX (Wang et al, 2015a), 10-hydroxycamptothecin with DOX , can be found in some studies for enhancing anticancer efficacy utilizing combination chemotherapy.…”

Section: The Model Drugs In Ndcdsmentioning

confidence: 83%

Co-delivery nanoparticles of anti-cancer drugs for improving chemotherapy efficacy

Sun

Yu³

et al. 2017

Drug Delivery

180

View full text Add to dashboard Cite

To achieve superior therapeutic efficacy, the combination chemotherapy using two or more anticancer drugs in clinical practice has been generally accepted as a feasible strategy. On account of the concept of combination chemotherapy, co-delivery of anticancer drugs with nanotechnology gradually becomes a desired strategy and one of the research frontiers on modern drug delivery. In recent years, nano drug co-delivery system (NDCDS), which loads at least two anticancer drugs with different physicochemical and pharmacological properties into a combination delivery system, has achieved rapid development. NDCDS synergistically inhibited the growth of the tumor compared with the free drugs. In this review, we highlighted the current state of co-delivery nanoparticles and the most commonly used nanomaterial, discussed challenges and strategies, and prospect future development. ARTICLE HISTORY

show abstract

“…When compared with the free drugs, the nanoparticle formulated drugs were significantly more effective and less toxic both in vitro and in vivo. [103][104][105] …”

Section: Nanomedicine In Combination Therapymentioning

confidence: 99%

Therapeutic strategies for targeting cancer stem cells

Kim¹,

Siegler²,

Siriwon³

et al. 2016

JCMT

View full text Add to dashboard Cite

The therapeutic limitations of conventional chemotherapeutic drugs present a challenge for cancer therapy; these shortcomings are largely attributed to the ability of cancer cells to repopulate and metastasize after initial therapies. Compelling evidence suggests that cancer stem cells (CSCs) have a crucial impact in current shortcomings of cancer therapy because they are largely responsible for tumor initiation, relapse, metastasis, and chemo-resistance. Thus, a better understanding of the properties and mechanisms underlying CSC resistance to treatments is necessary to improve patient outcomes and survival rates. In this review, the authors characterize and compare different CSC-specific biomarkers that are present in various types of tumors. We further discuss multiple targeting approaches currently in preclinical or clinical testing that show great potential for targeting CSCs. This review discusses numerous strategies to eliminate CSCs by targeting surface biomarkers, regulating CSC-associated oncogenes and signaling pathways, inhibiting drug-efflux pumps involved in drug resistance, modulating the tumor microenvironment and immune system, and applying drug combination therapy using nanomedicine.

show abstract

Co-delivery of daunomycin and oxaliplatin by biodegradable polymers for safer and more efficacious combination therapy

Cited by 110 publications

References 44 publications

Platinum covalent shell cross-linked micelles designed to deliver doxorubicin for synergistic combination cancer therapy

Platinum covalent shell cross-linked micelles designed to deliver doxorubicin for synergistic combination cancer therapy

Co-delivery nanoparticles of anti-cancer drugs for improving chemotherapy efficacy

Therapeutic strategies for targeting cancer stem cells

Contact Info

Product

Resources

About